At the start of June, more than 30,000 oncology experts will flood into Chicago for the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting.
The focus, as always, will be on data from the most exciting cancer drugs and tests. Expect updates on CAR-T immunotherapies, checkpoint inhibitors, companion diagnostics and the like.
Amid the noise, New York City-based Medidata will be presenting new evidence to support the use of so-called “synthetic control arms” or SCAs, which address a major limitation in clinical trial designs.
According to a company statement, “Medidata is the first technology company ever selected by ASCO to present its scientific innovation to advance clinical research and further drug development in oncology and beyond.”
In other words, it’s not often that they give the mic to someone discussing a tool for clinical trials.
Founded in 1999, Medidata is a software as a service (SaaS) company that offers a diverse range of products and services to both trial sponsors and CROs. Its team will present two studies at ASCO this year. One concerns an algorithm designed to generate new genomic information; the other discusses a new approach to the use of historical controls.
Randomized controlled trials (RCTs) have long been the gold standard for proving therapeutic safety and efficacy. From the beginning, patients are randomly assigned to two or more groups. One cohort is dosed with a placebo…